27 completed, 8 terminated, 6 recruiting, 4 unknown. 19 Phase 2, 12 Phase 3, 9 Phase 1, 6 Not applicable, 4 Phase 4.
Follow Menarini Group: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Medical Imaging to Re-evaluate Elacestrant Clinical Usage Elacestrant - ER+ / HER2- Advanced Breast Cancer | Phase 2 | Not yet recruiting | Jules Bordet Institute | 160 | 2026-09-13 | 2026-08-10 |
| PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) Capecitabine, Elacestrant - Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer | Phase 2 | Recruiting | Kristina A. Fanucci | 297 | 2026-01-16 | 2026-08-26 |
| A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer Elacestrant, Leuprorelin - Breast Cancer | Phase 2 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 140 | 2025-10-06 | 2025-12-01 |
| Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic Breast Cancer in Spain Liquid Biopsy, Archival Tumor DNA - Metastatic Breast Cancer | Recruiting | SOLTI Breast Cancer Research Group | 300 | 2025-05-20 | 2025-05-28 | |
| A Study to Assess How Vaborem® is Taking up in the Body and Tolerated in Paediatric Patients With Gram Negative Infections, Including But Not Restricted to Complicated Urinary Tract Infections Meropenem plus vaborbactam - Gram Negative Infections | Phase 2 | Recruiting | Menarini Group | 44 | 2025-02-18 | 2026-10-07 |
| MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) MEN1703, Glofitamab - Non-Hodgkin Lymphoma, B-cell | Phase 2 | Recruiting | Ryvu Therapeutics SA | 178 | 2024-12-05 | 2026-09-18 |
| Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) Elacestrant, Tamoxifen, Letrozole 2.5mg - ER-positive Breast Cancer, HER2-negative Breast Cancer | Phase 3 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 220 | 2023-12-15 | 2026-10-07 |
| Effectiveness and Safety of Pigment Solution Program (PSP) as Adjuvant Therapy in Melasma Pigment Solution Program - Melasma | Not applicable | Unknown | Dr.dr.Irma Bernadette, SpKK (K) | 33 | 2023-09-25 | 2023-12-18 |
| Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma Selinexor - Multiple Myeloma | Active not recruiting | iOMEDICO AG | 75 | 2023-06-28 | 2026-01-14 | |
| PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin MEN1611, Eribulin - Breast Cancer, Advanced Breast Cancer | Phase 2 | Active not recruiting | MedSIR | 14 | 2023-05-24 | 2026-03-10 |
| Responses to CPET in Subjects With Persistent Exercise Intolerance After COVID-19: an Open-Source Exercise Network COVID-19 | Completed | Association pour la Complementarite des Connaissances et des Pratiques de la Pneumologie | 1200 | 2022-07-15 | 2024-05-21 | |
| MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01) MEN1611, Cetuximab - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Completed | Menarini Group | 29 | 2020-07-20 | 2025-05-01 |
| Delafloxacin IV and OS Administration Compared to Best Available Therapy in Patients With Surgical Site Infections Delafloxacin, Vancomycin, Linezolid - Surgical Site Infection | Phase 3 | Terminated | Menarini Group | 268 | 2019-09-25 | 2022-02-02 |
| Motivational Interviewing and Self-care in Type 1 Diabetes: Randomized Controlled Clinical Trial. motivational interviewing - Type1diabetes | Not applicable | Unknown | Hospital Universitario Insular Gran Canaria | 60 | 2019-03-07 | 2019-04-08 |
| MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer MEN1611, Trastuzumab, Fulvestrant - Advanced or Metastatic Breast Cancer | Phase 1 | Completed | Menarini Group | 62 | 2018-11-13 | 2025-06-26 |
| MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study MEN1309 - Metastatic Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma | Phase 1 | Terminated | Menarini Group | 28 | 2017-08-28 | 2021-09-28 |
| MEN1703 (SEL24) in Participants With Acute Myeloid Leukemia MEN1703 - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Menarini Group | 73 | 2017-03-10 | 2025-04-29 |
| Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults Febuxostat - Tumor Lysis Syndrome | Phase 1 / Phase 2 | Terminated | Menarini Group | 30 | 2017-02-27 | 2021-06-03 |
| Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer Active CTC Assessment - Adenocarcinoma of the Prostate | Phase 3 | Terminated | Institute of Cancer Research, United Kingdom | 12 | 2017-01-11 | 2021-01-06 |
| Comparative Effects of Nebivolol and Carvedilol on Diastolic Function in the Elderly Heart Failure Patients Nebivolol, Carvedilol - Heart Failure | Not applicable | Unknown | Dong-A University | 62 | 2016-12-01 | 2018-02-05 |
Showing 20 of 50. Sign in to see all of them.
Breast Neoplasms (6) · Intestinal Diseases (5) · Irritable Bowel Syndrome (5) · Acute Pain (4) · Colic (4) · Pain, Postoperative (4) · Diarrhea (3) · Recurrence (3) · Diabetes Mellitus (2) · Diabetes Mellitus, Type 1 (2) · Heart Failure (2) · Leukemia, Myeloid, Acute (2) · Lymphoma, Non-Hodgkin (2) · Osteoarthritis, Knee (2) · Pulmonary Disease, Chronic Obstructive (2)
Sugars (5) · dexketoprofen trometamol (5) · ibodutant (5) · MEN 11420 (4) · elacestrant (4) · Nebivolol (3) · (4-amino-5-(4-(4-(2,4-dichloro-3-(2,4-dimethyl-8-quinolyloxymethyl)phenylsulfonamido)tetrahydro-2H-4-pyranoylcarbonyl)piperazino)-5-oxopentyl)(trimethyl)ammonium (2) · Carvedilol (2) · Continuous Glucose Monitoring (2) · Febuxostat (2) · Tramadol (2) · aclidinium bromide (2) · 6-methylbenzo(b)thiophene-2-carboxylic acid (1-(2-phenyl-((1-(tetrahydropyran-4-ylmethyl)piperidin-4-ylmethyl)carbamoyl)ethylcarbamoyl)cyclophenyl)amide (1) · Acetaminophen (1) · Allopurinol (1)
Spain (23) · Italy (22) · Germany (19) · Poland (14) · France (12) · United Kingdom (12) · United States (10) · Hungary (9) · Czechia (8) · Belgium (5) · Latvia (4) · Russia (4) · Sweden (4) · Austria (3) · Bulgaria (3)
Jan Tack, Professor (3) · Andrew Moore, Professor (2) · Henry J McQuay, Professor (2) · Lin Chang, Professor (2) · Thomas R. Pieber, MD (2) · Adriano Venditti, Professor, MD (1) · Alan J Camm, Professor (1) · Andrej Zeyfang, MD (1) · Angela Capriati, MD, PhD (1) · Anke Braun, MD (1) · Anna Pluzanska, MD (1) · Antonio Casado, MD (1) · Antonio Llombart-Cussac, MD (1) · Bernard Aguilaniu, M.D. PhD (1)
PMID 16035489, PMID 16601194, PMID 17188619, PMID 17911499, PMID 19430350, PMID 20593911, PMID 23478059, PMID 24952307, PMID 25271602, PMID 25602175, PMID 26123824, PMID 26216382, PMID 26787797, PMID 26801905, PMID 27196574, PMID 27809882, PMID 30782886, PMID 33362714, PMID 35342289, PMID 36913051, PMID 40908975, PMID 41536779
2014 (4), 2008 (1), 2009 (1), 2016 (1), 2017 (1), 2018 (1), 2019 (1), 2025 (1)